Highlights Newsletter 1

This newsletter presents you the following key sessions:

1. PODCAST with prof. Bruno Sangro about the CheckMate 459 trial

2. Capecitabine-irinotecan (CAPIRI) not superior to irinotecan monotherapy as second-line treatment for
    patients with advanced gall bladder cancers

3. First-line liposomal irinotecan plus 5-FU and oxaliplatin has promising antitumor activity in patients
    with previously untreated pancreatic ductal adenocarcinoma

4. Trastuzumab deruxtecan effective in patients with HER2-positive advanced gastric or gastroesophageal
    junction adenocarcinoma

5. Triplet combination of encorafenib, binimetinib and cetuximab safe and effective in patients with
    BRAF^V600E-mutant metastatic colorectal cancer